ANAVEX 3-71, also known as AF710B, is a muscarinic acetylcholine M1 receptor positive allosteric modulator and sigma σ1 receptor agonist which is under development for the treatment of schizophrenia, Alzheimer's disease, frontotemporal dementia, other neurodegenerative disorders, and Parkinson's disease. It is taken orally. The drug shows pro-cognitive-like, neuroprotective, and neurorestorative effects in preclinical research. The pharmacokinetics of ANAVEX 3-71 have been studied in humans. ANAVEX 3-71 is under development by Anavex Life Sciences. As of October 2025, it is in phase 2 clinical trials for schizophrenia and phase 1 trials for Alzheimer's disease, frontotemporal dementia, and other neurodegenerative disorders, whereas no recent development has been reported for Parkinson's disease.
See also List of investigational antipsychotics List of investigational Parkinson's disease drugs ANAVEX 1-41 Blarcamesine (ANAVEX 2-73)
References